Nateglinide-d5
(Synonyms: 那格列奈-D5,A4166 D5; Senaglinide D5) 目录号 : GC47751
An internal standard for the quantification of nateglinide
Cas No.:1227666-13-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Nateglinide-d5 is intended for use as an internal standard for the quantification of nateglinide by GC- or LC-MS. Nateglinide is a hypoglycemic agent.1,2,3 It induces insulin and somatostatin release from perfused rat pancreas when used at concentrations ranging from 0.03 to 3 μM.1 Nateglinide (3 µM) increases intracellular calcium levels in isolated rat pancreatic β cells, an effect that can be inhibited by the L-type calcium channel blocker nitrendipine . Nateglinide-induced secretion of insulin and somatostatin and calcium influx is also reversed by the potassium channel activator diazoxide . Oral administration of nateglinide (1.6 mg/kg) reduces blood glucose levels by 20% in fasted mice.2 It also decreases blood glucose levels in an oral glucose tolerance test in normal rats, genetically diabetic KK mice, and a rat model of diabetes induced by streptozotocin .3 Formulations containing nateglinide have been used in the treatment of type 2 diabetes.
1.Fujitani, S., Ikenoue, T., Akiyoshi, M., et al.Somatostatin and insulin secretion due to common mechanisms by a new hypoglycemic agent, A-4166, in perfused rat pancreasMetabolism45(2)184-189(1996) 2.Shinkai, H., Toi, K., Kumashiro, I., et al.N-acylphenylalanines and related compounds. A new class of oral hypoglycemic agentsJ. Med. Chem.31(11)2092-2097(1988) 3.Sato, Y., Nishikawa, M., Shinkai, H., et al.Possibility of ideal blood glucose control by a new oral hypoglycemic agent, N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine (A-4166), and its stimulatory effect on insulin secretion in animalsDiabetes Res. Clin. Pract.12(1)53-59(1991)
| Cas No. | 1227666-13-8 | SDF | |
| 别名 | 那格列奈-D5,A4166 D5; Senaglinide D5 | ||
| Canonical SMILES | CC(C)[C@H]1CC[C@H](C(N[C@H](CC2=C([2H])C([2H])=C([2H])C([2H])=C2[2H])C(O)=O)=O)CC1 | ||
| 分子式 | C19H22D5NO3 | 分子量 | 322.5 |
| 溶解度 | DMSO : 100 mg/mL (310.13 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.1008 mL | 15.5039 mL | 31.0078 mL |
| 5 mM | 0.6202 mL | 3.1008 mL | 6.2016 mL |
| 10 mM | 0.3101 mL | 1.5504 mL | 3.1008 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。